This master lecture series will focus on providing comprehensive and latest oral and intravenous pharmacotherapy options for cancer patients. With the exponential growth in the number of oncology pharmaceutical products available and increased innovation calling for utilization of multiple lines of therapy and expanding reliability on precision medicine to identify biomarker indicators to establish individualized, anti-tumor activity, it is paramount to disseminate the latest scientific evidence among the clinical oncology care team to afford cancer patients cutting-edge and evidenced-based treatment options.
FLASCO50 – 50% off of the registration fee for members (Offer limited to HCPs)
